NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, will present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11, at 2:45 p.m. ET. The conference is being held at the Crowne Plaza Times Square in New York.
A live audio webcast of the presentation will be available under the Investors section of the Company's website at www.karyopharm.com, where it will be archived for 90 days.
ASH Investor Reception
Karyopharm will host an investor reception and webcast at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which is taking place December 7-10, 2013 in New Orleans. The reception will take place on Monday, December 9th, 2013, from 12:00 p.m. — 1:30 p.m. CT (1:00 p.m. — 2:30 p.m. ET), and will include a discussion of upcoming milestones as well as interim results being presented at ASH from the Phase 1 trial of Selinexor, Karyopharm's lead drug candidate, in hematologic malignancies.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell, thereby leading to their accumulation in the nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
Any statements in this press release about future expectations, plans and prospects for Karyopharm constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the unproven nature of our discovery and development approach and uncertainties inherent in preclinical testing and clinical trials, among other factors discussed in the "Risk Factors" section of the prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Beth DelGiacco Stern Investor Relations, Inc. email@example.com 212-362-1200